Results 121 to 130 of about 34,148 (221)

Moxifloxacin treatment.

, 2016
We compare results of model simulation with data from [9] under Moxifloxacin treatment. Therapy starts 24 hours after infection and is continued every 12h.
Martin Witzenrath (167419), Sibylle Schirm (418795), Markus Scholz (157675), Peter Ahnert (620332), Sandra Wienhold (2794108), Geraldine Nouailles-Kursar (2794114), Holger Mueller-Redetzky (2794111), Markus Loeffler (52391)   +7 more
core   +1 more source

The Role of Chest Radiograph, Procalcitonin and Moxifloxacin in Diagnosis and Management of Breast Cancer Patients with COVID-19

Acta Medica Indonesiana, 2020
Global widespread of current coronavirus disease 2019 (COVID-19) pandemic has emerged huge predicament to healthcare systems globally. This disease caused by a new beta-type coronavirus, known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
Ikhwan Rinaldi, Abdul Muthalib, Pujo Astowo, Bambang Irawan, Nelly Susanto, Lingga Magdalena, Ilham H.R. Tulus Maha, Satrio Wicaksono   +7 more
doaj  

Clostridioides difficile as a Zoonotic and Foodborne Pathogen: Reviewing the Global Evidence and South African Data

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Clostridioides difficile infections are increasingly problematic in areas with already burdened healthcare systems. From a One‐Health perspective, a lack of surveillance in developing countries greatly contributes to the limited information available on the zoonotic and foodborne potential of C. difficile.
M. Gouws, P. E. Strydom, D. Rip
wiley   +1 more source

Gender analysis of moxifloxacin clinical trials

, 2013
Purpose: To determine the inclusion of women and the sex-stratification of results in moxifloxacin Clinical Trials (CTs), and to establish whether these CTs considered issues that specifically affect women, such as pregnancy and use of hormonal therapies.
Ruiz-Cantero, María Teresa, Elisa Chilet-Rosell, Ma Teresa Ruiz-Cantero, Chilet Rosell, Elisa, Ma Angeles Pardo, Pardo López, María Ángeles   +5 more
core   +1 more source

Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment

Pharmaceutics
Background/Objectives: We report the development of a novel intraocular sustained-release implantable pharmaceutical formulation, designed to be placed in the anterior chamber of the eye after cataract surgery.
Pablo Miranda, Luis Ignacio Tártara, Analía Castro, Patricia Zimet, Ricardo Faccio, Santiago Daniel Palma, Álvaro W. Mombrú, Helena Pardo   +7 more
doaj   +1 more source

Facing Antimicrobial Resistance and Virulence in Streptococcus agalactiae During Late Pregnancy: Evaluation of Lactobacilli as a Supportive Approach

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Integrated phenotypic, genotypic, and functional characterization of clinical Streptococcus agalactiae (Group B streptococcus, GBS) isolates from maternal carriage. Combination of selected Lactobacillus species effectively antagonize S. agalactiae by limiting bacterial growth, preserving epithelial cell viability, and reducing pathogen adhesion ...
Astri D. Tagueha, Giulia Radocchia, Daniela Scribano, Matteo Lo Scalzo, Giacinto Panella, Serena Schippa, Giovanni Gherardi, Roberta Creti, Ilaria Marani, Giovanna Alfarone, Monica Imperi, Massimiliano Marazzato, Lucia Nencioni, Paola Checconi, Dolores Limongi, Anna Teresa Palamara, Cecilia Ambrosi   +16 more
wiley   +1 more source

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials

IJTLD Open
BACKGROUND: In STAND and SimpliciTB, clinical trials for drug-susceptible TB, regimens containing pretomanid, pyrazinamide, and other agents (PaZX) had more hepatotoxicity than the standard-of-care regimen of isoniazid, rifampicin, pyrazinamide, and ...
J. Nedelman, M. Li, M. Olugbosi, R. Bruning-Barry, J. Ambroso, M. Cevik, S. Gillespie, D.J. Sloan, M. Beumont, E. Sun   +9 more
doaj   +1 more source

Smart Polymer‐Based Drug Delivery Systems for Managing Infective Conjunctivitis: Advances and Future Prospects

Nano Select, Volume 7, Issue 6, June 2026.
The introduction covers the background and significance of conjunctivitis. It continues with a review of etiology, epidemiology, and clinical manifestations. Diagnostic methods are described, followed by discussions on pathophysiology and classification. Current treatment strategies, preventive measures, and therapeutic challenges are analyzed.
Xia Linkang, Marwan Abdelmahmoud Abdelkarim Maki, Saad Tayyab, Sachin Thakur, Pankaj Kumar, Ritu Karwasra, Mahesh Harihar Behare, Nitin Sharma, Wan Hamirul Bahrin Wan Kamal, Oganeswary Kobi, Kushagra Khanna, Mogana Rajagopal   +11 more
wiley   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops

Microorganisms
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic available for ophthalmic use. It inhibits two enzymes involved in bacterial DNA synthesis, covering Gram-positive and Gram-negative pathogens. This spectrum allows for the formulation of self-
Lorenzo Drago
doaj   +1 more source